Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15634MR)

This product GTTS-WQ15634MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNFRSF13C gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_052945.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 115650
UniProt ID Q96RJ3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ15634MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8153MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HL036337
GTTS-WQ10936MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ8674MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ11345MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-551
GTTS-WQ10859MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ5517MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ1871MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AGEN1884
GTTS-WQ8105MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW